

Cover Story
FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.
In Brief
Clinical Roundup


Drugs & Targets


Trending Stories
- Narjust Duma named associate director of the Cancer Care Equity Program at DFCI, Harvard Medical School
- Robert Stone: City of Hope aims to transform cancer care nationally through new models, partnerships
- Biden commits to creating “ARPA-H” research body in visit to Ohio State
- Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44
- The Cancer Letter gets a new website
- Abecma receives FDA approval for multiple myeloma